Vistara Bioscience
Private Company
Funding information not available
Overview
Vistara Bioscience is a private, early-stage biotech tools and services company that has developed a platform centered on proteomics and post-translational modifications. Its core offerings include a catalog of over 5,000 PTM-modified proteins, suggested clinical targets, custom assay services for degrader safety assessment, and cell modification services using bioactive peptides. The company appears to be pre-revenue, serving as a research enabler for pharmaceutical and biotech partners rather than developing its own drug pipeline, positioning itself at the intersection of the growing targeted protein degradation and PTM analysis markets.
Technology Platform
A proteomics-focused platform built on a library of >5,000 post-translationally modified (PTM) proteins, specialized assay services for cereblon and degrader safety assessment, and cell modification capabilities using bioactive peptides for target validation.
Opportunities
Risk Factors
Competitive Landscape
Vistara competes in the broad drug discovery tools and services market, facing competition from large reagent vendors (e.g., Thermo Fisher, Abcam) and specialized CROs. Its niche in PTM proteins and cereblon-specific assays is less crowded but may attract competitors as the targeted protein degradation field matures. Differentiation will rely on protein quality, assay sophistication, and speed of custom service.